Protagonist Therapeutics Appoints New CMO, Adds Director
Ticker: PTGX · Form: 8-K · Filed: Sep 20, 2024 · CIK: 1377121
Sentiment: neutral
Topics: management-change, board-appointment, executive-compensation
TL;DR
Protagonist Therapeutics beefs up leadership with a new CMO and board member.
AI Summary
Protagonist Therapeutics, Inc. announced on September 17, 2024, the appointment of Dr. Jonathan G. Drachman as Chief Medical Officer and the election of Ms. Sarah E. Kelly to its Board of Directors. The company also disclosed compensatory arrangements for its named executive officers, including Dr. Drachman.
Why It Matters
The appointment of a new Chief Medical Officer and a board member can signal strategic shifts or new directions for the company's drug development pipeline.
Risk Assessment
Risk Level: medium — Changes in key executive and board positions can indicate internal shifts that may impact future strategy and performance.
Key Players & Entities
- Protagonist Therapeutics, Inc. (company) — Registrant
- Dr. Jonathan G. Drachman (person) — Appointed Chief Medical Officer
- Ms. Sarah E. Kelly (person) — Elected to Board of Directors
- September 17, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer?
Dr. Jonathan G. Drachman has been appointed as the new Chief Medical Officer.
Who has been elected to the Board of Directors?
Ms. Sarah E. Kelly has been elected to the Board of Directors.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is September 17, 2024.
What is the company's state of incorporation?
The company's state of incorporation is Delaware.
What is the company's IRS Employer Identification No.?
The company's IRS Employer Identification No. is 98-0505495.
Filing Stats: 488 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-09-20 16:05:13
Key Financial Figures
- $0.00001 — h registered Common Stock, par value $0.00001 PTGX The Nasdaq Stock Market LLC
Filing Documents
- tm2424445d1_8k.htm (8-K) — 25KB
- 0001104659-24-101688.txt ( ) — 194KB
- ptgx-20240917.xsd (EX-101.SCH) — 3KB
- ptgx-20240917_lab.xml (EX-101.LAB) — 33KB
- ptgx-20240917_pre.xml (EX-101.PRE) — 22KB
- tm2424445d1_8k_htm.xml (XML) — 4KB
02. Departure of Directors
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 17, 2024, Daniel N. Swisher Jr., a member of the Board of Directors (the "Board") of Protagonist Therapeutics, Inc. (the "Company") and a member of the Audit Committee of the Board, resigned from the Board, effective September 17, 2024. Mr. Swisher did not advise the Company of any disagreement with the Company on any matter relating to its operations, policies or practices. Mr. Swisher will continue to serve as an advisor to the Company pursuant to an advisory agreement. Effective September 19, 2024, Sarah A. O'Dowd, a member of the Board, was appointed to the Audit Committee of the Board, and the size of the Company's Board of Directors was reduced from seven to six. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Protagonist Therapeutics, Inc. Dated: September 19, 2024 By: /s/ Asif Ali Asif Ali Chief Financial Officer